Bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract.

Abstract

OBJECTIVE:

To analyse the clinical and therapeutic consequences of bacillus Calmette-Guérin (BCG) perfusion therapy for carcinoma in situ (CIS) of the upper urinary tract.

PATIENTS AND METHODS:

Eight pyelo-ureteric systems in five patients with cytologically confirmed CIS of the upper urinary tract were treated using perfusion of BCG through a percutaneous nephrostomy tube in five and a retrograde ureteric catheter in three. Follow-up cystoscopy, retrograde pyelography and selective urinary cytology were obtained 4 weeks after the last treatment and every 3 months thereafter.

RESULTS:

In three patients (five pyelo-ureteric systems) the cytology remained negative for 10-46 months after the treatment was completed. The remaining two patients (three pyelo-ureteric systems) had persistently positive cytology. Of two patients who received BCG therapy through a ureteric catheter, one developed a ureteric stricture and the other developed renal tuberculosis.

CONCLUSIONS:

Although long-term adaptation to a nephrostomy tube disturbs the quality of life of the patient, percutaneous perfusion therapy through a nephrostomy tube seems to be safer than retrograde perfusion through a ureteric catheter.

• Authors: H Yokogi, Y Wada, M Mizutani, M Igawa, T Ishibe
• Journal: British journal of urology (Br J Urol) Vol. 77 Issue 5 Pg. 676-9 (May 1996) ISSN: 0007-1331 [Print] England
• PMID: 8689109 (Publication Type: Journal Article)

Chemical References

• BCG Vaccine

Topics

• Aged
• BCG Vaccine (therapeutic use)
• Carcinoma in Situ (therapy)
• Chemotherapy, Cancer, Regional Perfusion
• Female
• Humans
• Kidney Neoplasms (therapy)
• Male
• Middle Aged
• Treatment Outcome
• Ureteral Neoplasms (therapy)
• Urinary Bladder Neoplasms (therapy)
• Urinary Catheterization